IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Asston Pharmaceuticals Ltd.
Issue Open Date 09-Jul-25  
Issue Closing Date 11-Jul-25  
Application Money 100  
Allotment Money  
Price Band 115 - 123  
Minimium Application No. 1000  
Issue Size (Shares) 2241000  
Market Lot 1.00  
Objective
1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit;2. Funding the incremental working capital requirements of our Company;3. Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by ourCompany; and4. General Corporate Purposes
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors       NA  
Qualified Institutional Buyers       NA  
Retail Individual Investors       NA  
Business Description
Our Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products indomestic and various African markets. Our Company operates under brand “Asston”. Presently, our Company is involved in thebusiness of manufa
more...
Promoter's Holding
Total Share Capital   4331680  
Offered to Public   2241600  
Promoter's Holding (Pre-Issue)   69.07  
Promoter's Holding (Post-Issue)    
Address
4th Floor
Office No A-431
Balaji Bhavan
Plot No 42 A
Sector-11 Cbd Belapur
Navi Mumbai
Thane ,
Maharashtra ,
400614
Phone: 022 49731419/49731411
Email: info@asstonpharmaceuticals.com
Website: www.asstonpharmaceuticals.com
Registrar
Maashitla Securities Pvt Ltd.
451
Krishna Apra Business
Square
Netaji Subhash Place

Pitampura
New Delhi
Listed at
BSE
Lead Manager
Sobhagya Capital Options Ltd
Promoters
Ashish Narayan Sakalkar
Sachin Chandrakant Badakh
Saili Jayaram More
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.